American CryoStem Partners with Rutgers for Novel Wound Care Product

Regenerative medicine is constantly discovering new inroads to potential therapies utilizing adult stem cells for a variety of life threatening or debilitating conditions and diseases. Progress has accelerated in the past few years, fueled in part by President Obamas 2009 Executive Order 13505 that removed barriers in responsible research which has opened doors to examination of new ways of thinking. It has also aided in the emergence of research in the area of adipose (fat)-based stem cell therapy, which could prove to be a major breakthrough in regenerative medicine. Not only has early research at Johns Hopkins suggested the possibility of superior efficacy with Adipose-Derived Stem Cells, or ADSCs, in the treatment of glioblastoma (a severe form of brain cancer), but ADSCs are easily harvested, meaning that they could become a standard as the most reliable and abundant source of stem cells for research, cultures and therapeutic processes.

Akin to institutions like Harvards Dana-Farber and University of Texas MD Anderson being recognized as two of the worlds leading cancer research centers, certain institutions have become established as pioneering experts in stem cell research. Johns Hopkins and Rutgers University sit amongst the leaders in this arena. This bodes very well for American CryoStem Corp. (OTCQB:CRYO - News), a developer, marketer and global licensor of patented adipose tissue-based and cellular technologies that on Tuesday disclosed entering into Material Transfer Agreements with three leading research scientists at Rutgers.

American CryoStem is a unique end-to-end provider in the stem cell business with its broad spectrum of technologies focused on adipose tissue. The small company is penetrating the cosmeceutical industry in addition to the adipose tissue cryopreservation business that is dominated by Life Technologies Corp. (NASDAQ:LIFE - News). Additional offerings in stem cell processing and banking services diversify the company into competition with higher-priced peers like Cryo-Cell International, Inc. (OTCQB:CCEL - News), a Florida-based company specializing in cell preservation for family use. Now, with this announcement, American Cryostem is taking their experience with ADSCs into the therapeutic arena.

Combine the diversity of the companys revenue streams with the emergence of ADSCs as an easier and perhaps more effective source of stem cells and American Cryostem starts to look severely undervalued compared to a company like Advanced Cell Technology, Inc. (OTCQB:ACTC - News). Advanced Cell Technology is focusing on a few therapeutic platforms for their adult and human embryonic stem cells, with the Phase 1 trials for the Retinal Pigment Epithelium Program the furthest along. American Cryostem has growing revenue now with multiple short- to mid-term catalysts and trades at less than 10 percent of the ACTC valuation.

Rutgers Dean of Mathematical and Physical Sciences, Dr. Kathryn Uhrich, hatched the idea of the collaboration with American CyroStem that now includes Drs. KiBum Lee and Prabhas Moghe as well. Per the agreement, the doctors will be utilizing American CryoStems autologous ADSCs and patented, serum free, GMP grade cell culture and differentiation mediums with the goal of developing and commercializing new cellular therapies in the global wound care market, estimated to be approximately $5 billion currently.

To read the full release, click here: http://www.americancryostem.com/american-cryostem-to-collaborate-with-rutgers-university-on-adipose-derived-stem-cell-research/

Sign Up to Receive Email Updates on American Cryostem: http://www.emerginggrowthcorp.com/emailassets/cryo/cryo_landing.php

About Emerging Growth LLC: EGC is a marketing and consulting firm that specializes in creating ongoing communications strategies for public and private companies. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx

Originally posted here:
American CryoStem Partners with Rutgers for Novel Wound Care Product